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Stress-activated miR-21/miR-21* in hepatocytes promotes lipid and glucose metabolic 
disorders associated with high-fat diet consumption.  
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ABSTRACT 
 
Objective: miR-21 is an oncomir highly upregulated in hepatocellular carcinoma, but also in 
early stages of liver diseases characterized by the presence of steatosis. Whether upregulation 
of miR-21 contributes to hepatic metabolic disorders and their progression towards cancer is 
unknown. This study aims at investigating the role of miR-21/miR-21* in early stages of 
metabolic liver disorders associated with diet-induced obesity (DIO). 
Design: Constitutive miR-21/miR-21* knockout (miR21KO) and liver-specific miR-21/miR-
21* knockout (LImiR21KO) mice were generated. Mice were then fed with high-fat diet 
(HFD) and alterations of the lipid and glucose metabolism were investigated. Serum and ex-
vivo explanted liver tissue were analyzed.  
Results: Under normal breeding conditions and standard diet, miR-21/miR-21* deletion in 
mice was not associated with any detectable phenotypic alterations. However, when mice 
were challenged with an obesogenic diet, glucose intolerance, steatosis and adiposity were 
improved in mice lacking miR-21/miR-21*. Deletion of miR-21/miR-21* specifically in 
hepatocytes led to similar improvements in mice fed a HFD, indicating a crucial role for 
hepatic miR-21/miR-21* in metabolic disorders associated with DIO. Further molecular 
analyses demonstrated that miR-21/miR-21* deletion in hepatocytes increases insulin 
sensitivity and modulates the expression of multiple key metabolic transcription factors 
involved in fatty acid uptake, de novo lipogenesis, gluconeogenesis and glucose output. 
Conclusion: Hepatic miR-21/miR-21* deficiency prevents glucose intolerance and steatosis 
in mice fed an obesogenic diet by altering the expression of several master metabolic 
regulators. This study point out miR-21/miR-21* as a potential therapeutic target for NAFLD 
and the metabolic syndrome. 
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SIGNIFICANCE OF THIS STUDY 
 
What is already known about this subject? 
 Upregulation of miR-21 expression is a general feature of tissue inflammation, fibrosis 
and of most human cancers including HCC. 
 miR-21 up-regulation occurs already in early stages of metabolic liver disorders and is 
associated with the presence of steatosis and insulin resistance in the liver of obese 
human, and of diet-induced rodent models of obesity. 
 Bioinformatics analyses predict more than 2500 genes potentially regulated by miR-
21/miR-21* and more than 100 miR-21/miR-21* targets, not predicted by classical 
software, have been validated experimentally in different cells/tissues. 
 
What are the new ﬁndings? 
 Deletion of miR-21/miR-21* is asymptomatic in mice bred in normal conditions.  
 miR-21/miR-21* in hepatocytes promotes systemic glucose intolerance, hepatic steatosis, 
hepatic insulin resistance and defects in hepatic gluconeogenesis, evoked by the 
consumption of an obesogenic diet. 
 Hepatic miR-21/miR-21* in mice fed an obesogenic diet alters directly, or indirectly, the 
expression of multiple master transcription factors regulating the lipid and glucose 
metabolism in hepatocytes. 
 
How might it impact on clinical practice in the foreseeable future? 
 miR-21/miR-21* are promising therapeutic targets for the treatment of fatty liver disease 
with various etiological factors. 
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INTRODUCTION 
 
Non-alcoholic fatty liver disease (NAFLD) represents the liver manifestation of metabolic 
disorders associated with obesity and diabetes.[1] Hepatic steatosis characterized by abnormal 
accumulation of lipid droplets in hepatocytes is the hallmark of NAFLD. Although the 
molecular mechanisms are still unclear, steatosis is often associated with insulin resistance 
(IR) and glucose intolerance, and can evolve to steatohepatitis and fibrosis with time.[2] Since 
hepatocellular carcinoma (HCC) might also occur as an end stage of NAFLD, these hepatic 
metabolic disorders could also be regarded as preneoplastic states of the liver. In this regard, 
alterations of glucose metabolism, e.g. increased glycolysis and energy production,[3] and 
deregulation of fatty acid/cholesterol metabolism, i.e. excessive lipid anabolism and storage, 
are now increasingly recognized to promote liver carcinogenesis.[4] 
Epigenetic mechanisms, in particular driven by microRNAs (miRNAs), play a major role in 
complex metabolic processes including insulin and glucose homeostasis, cholesterol and lipid 
metabolism, energy expenditure, adipogenesis and inflammation.[5, 6] MicroRNAs are short 
non-coding RNAs regulating gene expression either through the induction of specific mRNA 
targets degradation or by inhibiting their translation.[7] Interestingly, miRNAs expression is 
tissue-specific and may vary according to the metabolic requirements of the cell/organ.[8] 
Consequently, deregulation of miRNAs expression is often associated with metabolic 
disorders.[6] 
A wealth of studies has indicated that deregulated expression of specific hepatic miRNAs 
critically contributes to the development of liver-specific metabolic disorders, insulin 
resistance and cancer.[9, 10, 11, 12] Among them, miR-21 (miR-21-5p) is an oncomir highly 
up-regulated in most of the cancers examined so far.[13] Of importance, although miR-21 is 
highly expressed in hepatocytes, it is minimally active in normal physiological 
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conditions.[14] However, in pathological conditions, levels of active miR-21 are increased 
and its activity importantly contributes to molecular alterations triggering hepatic disorders. 
For example, increased miR-21 expression might play an important role in liver fibrosis, 
consistent with previous studies examining the role of miR-21 in kidney, heart and lung 
fibrosis.[15, 16, 17, 18, 19, 20] In cholangiocarcinoma and HCC, miR-21 is up-regulated, 
thereby inhibiting the expression of crucial tumour suppressors and favoring hepatic cells 
survival.[19, 21, 22, 23, 24] miR-21 also regulates early phases of liver regeneration following 
partial hepatectomy.[25, 26] Finally, the complementary passenger strand of miR-21 (miR-
21* or miR-21-3p), which normally undergoes degradation, was previously reported to be up-
regulated and to exert some functions in renal fibrosis and cardiac hypertrophy.[27, 28, 29] 
Interestingly, we and others have reported that miR-21 up-regulation occurs already in early 
stages of metabolic liver disorders and is associated with the presence of steatosis in the liver 
of obese human and of diet-induced rodent models of obesity.[30, 31, 32] Considering the 
concept where the hepatic metabolic reprogramming promotes inflammation and fibrosis and 
sustains oncogenic transformation, we generated conditional miR-21/miR-21* knockout mice 
to delineate in vivo the role of miR-21/miR-21* in alterations of hepatic lipid and glucose 
metabolism associated with consumption of fat-enriched diet. We selected this approach 
rather than using synthetic miR-21 or miR-21* inhibitors given the reported discrepant results 
obtained with genetic models of miR-21/miR-21* deletion or administration of synthetic miR-
21 inhibitors, in heart pathology for example.[33] Herein, we show that miR-21/miR-21* 
expression in hepatocytes promotes systemic glucose intolerance, hepatic steatosis and 
defects in hepatic gluconeogenesis, evoked by the consumption of an obesogenic diet. 
Evidence is provided that, in mice fed an obesogenic diet, hepatic miR-21/miR-21* directly 
and indirectly regulates the expression of multiple master transcription factors regulating lipid 
and glucose metabolism in hepatocytes.  
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MATERIALS AND METHODS 
 
Reagents 
All reagents, devices, buffers, primers, culture media, kits, antibodies and diets are described 
in the Supplementary Materials and Methods.  
 
Animals 
We first generated miR-21
lox/lox
 mice where the 260 bp sequence containing the mir21 gene 
was flanked with two loxP sites via homologous recombination in ES cells using standard 
techniques (Supplementary Fig. S1A). Constitutive miR-21 knockout animals were obtained 
by crossing mice carrying two miR-21
lox
 alleles with a transgenic mice expressing the Cre 
recombinase under the control of a male germ cell-specific promoter (Ddx4-Cre transgene). 
Male Ddx4-Cre;miR-21
lox/lox
 mice were then used to produce animals with constitutive whole-
body miR-21 KO alleles (miR21KO mice). To achieve selective inactivation of miR-21 in 
hepatocytes, we mated miR-21
lox/lox
 mice with Alb-Cre-ER
T2 
transgenic mice expressing Cre-
ER
T2
 recombinase under the control of the albumin promoter,[34] a kind gift of Prof. D. 
Metzger and Prof. P. Chambon (University of Strasbourg, France). Although some leakage of 
the Cre activity was observed in hepatocyte as previously described,[35, 36] total 
recombinase activity was induced by subcutaneous administration of tamoxifen pellets 
(25mg/tablet) at 2 months of age, to fully delete the miR-21
 
alleles specifically in hepatocytes 
(LImiR21KO mice). All studies were carried out using mice with mixed genetic background 
(C57BL/6Ncr, 129S6), and miR-21 deletion was confirmed by conventional PCR-based 
genotyping and qRT-PCR for mature miR-21. The detailed protocols used to generate each 
mouse strain, and for their genotyping, are described in the Supplementary Materials and 
Methods.  
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Control miR-21
lox/lox
 mice (CTRL) and miR21KO mice were fed standard diet and tap water 
ad libitum until the age of two months. Mice of each strain were then randomly organized into 
two groups (n= 5-10) and submitted to a 4 weeks-long feeding period with high-fat diet 
(HFD: 60% cal/fat) or standard diet (CD: 5% cal/fat), matched for its composition with the 
HFD. CTRL and LImiR21KO mice were submitted to the same CD and HFD after tamoxifen 
administration. Food intake and body weight were monitored daily. At the end of the study, 
mice were euthanized, and blood and organs were collected. Animal care and experimental 
procedures were performed in accordance with the Swiss guidelines for animal 
experimentation and ethically approved by the Geneva Health head office.  
 
Metabolic phenotyping and EchoMRI 
Metabolic phenotyping of mice was performed for 72 hours using metabolic cages after 5 
days of adaptation prior of recording. EchoMRI was used to measure total fat and lean body 
mass. 
 
Glucose/pyruvate tolerance tests 
Glucose tolerance test (GTT) and pyruvate tolerance test (PTT) were performed as previously 
described.[37] Briefly, mice were starved overnight and a glucose load of 1.5g/kg, or a 
pyruvate load of 2g/kg, was administered i.p. Blood samples were collected, and glucose 
levels measured using a glucometer. 
 
Histology 
Liver samples were fixed in 4% paraformaldehyde and 6-m-thick sections were stained with 
hematoxylin/eosin (H&E) for morphological investigations. Oil Red O (ORO) staining was 
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performed on 6-m-thick cryo-sections to stain neutral lipids. Morphometric analysis of ORO 
staining was performed using the MetaMorph® software on at least 6 different fields of view 
per slide (> 30000 lipid droplets/sample).  
 
Tissues and plasma analyses 
Plasma levels of triglycerides (TG), cholesterol and glucose were determined by an automated 
analyzer. Lipid extraction from cryo-preserved hepatic samples was performed by 
chloroform/methanol extraction. TG and free cholesterol/cholesterol esters contents were 
measured by colorimetric enzymatic assays with commercial kits.  
 
Quantitative Real-Time PCR (qRT-PCR)  
RNA was extracted with Trizol reagent and 1μg was used for cDNA synthesis. PCR was 
performed with SYBR Green and Cyclophilin A (Ppia) was used to normalize gene 
expression. Primers sequences are listed in Supplementary Materials. For miRNA analysis, 10 
ng of total RNA was used for miRNA-specific cDNA synthesis with TaqMan MicroRNA RT 
kit and PCR was performed with Taqman MicroRNA Assays. U6/Sno202 were used to 
normalize miR-21 expression.  
 
Western Analyses 
Tissues and cells were lysed in ice-cold RIPA buffer. Equal amounts of proteins were resolved 
by 5-20% gradient SDS-PAGE and blotted to nitrocellulose membranes. Proteins were 
detected with specific primary antibodies and HRP-conjugated secondary antibodies using 
ECL. 
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Isolation of primary mouse hepatocytes (PMH) 
PMH were isolated by collagenase perfusion of the liver, as previously described.[38] Cells 
(6.25x10
4
/cm
2
) were seeded 6 hours in PMH medium and then starved overnight of FCS and 
insulin prior to insulin stimulation (10
-8
M, 15min).  
 
 
Bioinformatic predictions and Statistical Analysis 
Predictions of miR-21/miR-21* (mmu-miR-21-5p/mmu-miR-21-3p) targets were performed 
using the miRWalk2.0 atlas [39] allowing simultaneous predictions of miRNA targets for the 
DIANA-microTv4.0, DIANA-microT-CDS, miRanda-rel2010, mirBridge, miRDB4.0, 
miRmap, miRNAMap, doRiNA, PicTar2, PITA, RNA22v2, RNAhybrid2.1 and 
Targetscan6.2 algorithms. Only targets predicted by at least 6 programs were kept in 
consideration.  
Data are expressed as mean ± SEM. Statistical significances were assessed by 2-way ANOVA 
for GTT/PTT experiments and Welch's t-tests on log2-transformed (ratios) or untransformed 
values for other experiments. Differences were considered significant when *p<0.05, 
**p<0.01 or ***p<0.001. 
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RESULTS 
 
Metabolic phenotype of miR21KO mice 
To confirm deletion of miR-21/miR-21* in the miR21KO mice, we measured mature miR-21 
transcript level in the liver. Ablation of a 260 bp-long fragment including the miR-21 gene 
located in the 3’UTR of the Tmem49/Vmp-1 gene resulted in undetectable level of mature 
miR-21 transcripts (fig. S1A-B), and its passenger strand miR-21*, but did not affect 
Tmem49/Vmp-1 mRNA expression (supplementary figure S1C). Under standard chow diet 
(CD), miR21KO mice did not display any evident morphologic, metabolic or behavioural 
phenotype, except a slight but significant difference in fat versus lean mass body composition 
(figure 1A-B). In these conditions, miR-21/miR-21* deletion did not trigger upregulation of 
previously in vitro validated miR-21 targets (figure S1D), consistent with the recently 
reported inactive state of hepatic miR-21/miR-21* under physiological conditions.[14] 
However, after 4 weeks of high fat-containing diet (HFD), the ratio of lean versus fat mass 
was further increased in miR21KO as compared to CTRL mice (figure 1A-B). Although total 
body weight and food intake were unchanged, Labmaster analyses indicated that O2 
consumption, CO2 and heat production were significantly increased together with water intake 
in mice under HFD in the absence of miR-21/miR-21* (figure 1C-E) thereby suggesting an 
enhanced energy expenditure.  
 
Constitutive miR-21/miR-21* deficiency improves glucose and lipid metabolism in mice 
fed a HFD 
Glucose tolerance tests (GTT) were performed in mice fed a CD or HFD to evaluate the 
impact of miR-21/miR-21* deficiency on glucose tolerance. Although fed/fasted glycemia 
was similar between CTRL and miR21KO mice (data not shown), glucose intolerance 
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associated with HFD was significantly ameliorated in miR21KO mice (figure 2A). The liver 
importantly contributed to this improved glucose tolerance, since hepatic glucose production 
was strongly decreased in response to a pyruvate challenge (PTT, Pyruvate Tolerance Test) in 
miR21KO mice fed the HFD (figure 2B). miR-21/miR-21* deficiency deeply impacted also 
the hepatic lipid metabolism of mice stressed with HFD. Liver weights and ratios to body 
weights were similar in CTRL and miR21KO mice (figure 2C). However, hepatic steatosis 
associated with HFD consumption was significantly reduced in miR21KO mice as assessed 
by histological analyses of H&E stained liver sections and a decreased content of hepatic 
triglycerides (TG) but not cholesterol esters (figure 2D-E). Finally, TG and cholesterol levels 
in the sera of miR21KO mice also diminished, although not significantly for circulating TG 
(Supplementary figure S2A).  
Together these data indicate that constitutive deletion of miR-21/miR-21* attenuated systemic 
and hepatic metabolic disorders in mice challenged with a HFD. 
 
Deletion of miR-21/miR-21* specifically in hepatocytes is sufficient to improve glucose 
metabolism in mice challenged with HFD 
To further delineate the role of hepatic miR-21/miR-21* in DIO-associated metabolic 
disorders, we generated hepatocyte-specific inducible miR-21/miR-21* knockout mice 
(LImiR21KO). As shown in Supplementary figure S3, miR-21 deletion was observed 
specifically in the liver and not in other organs. Similar to that observed with miR21KO mice, 
LImiR21KO mice fed with HFD for 4 weeks displayed increased glucose tolerance and 
reduced hepatic glucose production in response to pyruvate (figure 3A), whereas mice fed a 
CD displayed only a weak inhibition of glucose output in response of a pyruvate challenge 
(Supplementary figure S4). Gene and protein expression of major transcriptionally regulated 
effectors controlling glucose turnover and output in the liver were further analysed in 
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LImiR21KO mice fed a HFD. A significant decrease in the expression of major glycolytic 
enzymes (Gck, Pdk1, Pkfl and Pklr) and of those promoting gluconeogenesis (Klf15 and 
G6PC) was observed consistent with decreased glycolytic fluxes and reduced 
gluconeogenesis and glucose output in the absence of miR-21/miR-21* (figure 3B-C). 
Western analyses of hepatic insulin signalling effectors in unstimulated liver extracts 
indicated a >2-fold increase of insulin receptor substrate 2 (IRS2) expression associated with 
significant increase in AKT phosphorylation on Ser473 and Rictor expression in LImiR21KO 
as compared to CTRL mice (figure 3D). In primary mouse hepatocytes (PMH) isolated from 
CTRL and LImiR21KO fed a HFD, phosphorylation of Akt on both Thr308 and Ser473 was 
also significantly increased by miR-21/miR-21* deficiency upon insulin stimulation (figure 
3E). 
These results indicate that hepatic miR-21/miR-21* alter systemic glucose tolerance and 
hepatic insulin sensitivity, gluconeogenesis and glucose output under stress conditions such as 
high fat feeding. 
 
Hepatic fatty acid uptake and lipogenesis are regulated by miR-21/miR-21* in mice fed a 
HFD 
As we observed with miR21KO mice, LImiR21KO mice fed a HFD had a higher ratio of lean 
versus fat mass body composition although their body and liver weight were similar to CTRL 
mice (figure 4A). However, hepatic steatosis, which was already severe after 4 weeks of HFD 
in CTRL mice, was strongly reduced in LImiR21KO mice, as assessed by histological 
staining and quantification of hepatic neutral lipid by H&E and Oil red O, and by measuring 
TG and cholesterol esters contents in hepatic tissues (figure 4B). To gain insights into the 
mechanisms by which miR-21/miR-21* deficiency prevents steatosis development with high 
fat feeding, we evaluated the expression of major rate limiting enzymes regulating hepatic 
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lipid metabolism. Expression of hepatic genes regulating cholesterol metabolism, fatty acid 
oxidation, esterification, intracellular transport, export and lipolysis were poorly affected by 
the absence of miR-21/miR-21* (figure S5). In contrast, important factors promoting fatty acid 
uptake and lipogenesis in hepatocytes were significantly downregulated in LImiR21KO mice 
under HFD, both at the mRNA and protein levels. In particular, expression of CD36, Fatp1 
and FAS, were strongly decreased, whereas the inhibitory phosphorylation of ACC increased 
(figure 4C-E).  
Together, these data indicate that absence of miR-21/miR-21* in hepatocytes of mice fed an 
obesogenic diet restrains steatosis development by reducing both lipogenesis and fatty acid 
uptake in hepatocytes.  
 
miR-21/miR-21* activity in hepatocytes affects multiple key factors involved in metabolic 
transcriptional regulation of hepatic glucose and lipid metabolism 
The hepatic regulation of lipid and glucose metabolism is under the control of several master 
transcriptional regulators acting intricately in complex networks. Among those, several are 
predicted as direct targets of miR-21/miR-21* through bioinformatics analyses and/or have 
been experimentally validated as miR-21/miR-21* targets (figure 5A-B). Expression of 
potential miR-21/miR-21*-targeted transcription factors, possibly associated with the 
phenotype of LImiR21KO mice stressed by a HFD, were investigated at the mRNA and 
protein levels. Consistent with increased insulin sensitivity and a reduced fatty acid uptake, de 
novo lipogenesis, gluconeogenesis and glucose output in hepatocytes, the protein expression 
of FOXO1, FOXA2, INSIG2, STAT3, and HNF4-α was significantly increased in 
LImiR21KO mice fed a HFD (figure 5C), whereas expression of PPAR-γ and active 
SREBP1C were importantly reduced (figure 5D). Interestingly, protein expressions were not 
always reflected at the mRNA levels suggesting a translational repression by miR-21/miR-21* 
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of the mRNAs of specific factors (e.g. FOXO1, FOXA2, STAT3, and HNF4-α. As expected 
with increased levels of INSIG2, expression of active SREPB1C was significantly reduced in 
LImiR21KO mice fed a HFD consistent with the reduced FAS levels and lipogenesis (figure 
4). Finally, although PPAR-α was previously described as a miR-21 target in vitro,[40, 41] its 
expression only slightly tends to increase in the liver of LImiR21KO mice and β-oxidation 
seems not to be stimulated, even slightly decreased as shown in Supplementary figure S5F. 
These data indicate that miR-21/miR-21* activity induced by HFD stress in hepatocytes leads 
directly and/or indirectly to combined alterations of multiple master metabolic factors 
regulating hepatic glucose and lipid metabolism.  
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DISCUSSION 
 
In this study, we provide in vivo evidence that miR-21/miR-21* are necessary factors for 
glucose intolerance and fatty liver disease in mice challenged with a HFD. Importantly, 
genetic deletion of miR-21/miR-21* in all tissues, or specifically in hepatocytes, led to similar 
improvements of metabolic disorders associated with high fat feeding in mice, thereby 
outlining the critical role of hepatocellular miR-21/miR-21* for metabolic homeostasis. Our 
data further suggest that HFD-associated miR-21/miR-21* activity leads to a complex 
alteration associated with glucose intolerance and steatosis in mice of multiple key 
transcriptional factors in hepatocytes controlling lipid and glucose metabolism.  
miR-21 is a highly expressed miRNA in the liver [42] and is further up-regulated with 
obesity,[30, 31, 32, 43, 44] steatohepatitis and fibrosis,[18, 31] as well as in 
cholangiocarcinoma and HCC.[21, 22] Actually, hundreds of miRNAs have been shown to be 
deregulated in human NAFLD, steatohepatitis and diabetes, each of them potentially 
controlling different and multiple aspects of hepatocyte biology, such as insulin sensitivity, 
lipid and glucose metabolism, ER and oxidative stresses, cell apoptosis and survival.[45, 46, 
47] Complexity in investigating the metabolic role of miR-21/miR-21* arises from the fact 
that miR-21/miR-21* appears to be inactive, although highly expressed, in the liver of mice 
bred in normal conditions.[14] Consistent with this concept, we could not detect any major 
phenotypic abnormalities under normal conditions in mice bearing a constitutive or liver-
specific deletion of miR-21/miR-21*. , Therefore, our data further highlight the role of miR-
21/miR-21* in hepatocytes as a stress microRNA promoting the onset of liver disorders upon 
metabolic challenge. 
Based on bioinformatics prediction analyses (miRwalk analyses) more than 1300 and 2500 
genes are potentially regulated by miR-21 and miR-21* respectively (Supplementary figure 
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S6). In addition, more than 100 miR-21/miR-21* targets, not predicted by classical software, 
have been validated experimentally in different cells/tissues further highlighting the 
complexity and limits of prediction algorithms for microRNAs of stress like miR-21/miR-
21*.[14] Finally, the regulatory functions of miR-21/miR-21* are likely cell/tissue specific, of 
weak amplitudes, but exerted on multiple genes involved in intricate molecular networks 
regulating different cellular processes.[24, 48] Based on these considerations, it is unlikely 
that the beneficial effects of miR-21/miR-21* deletion in hepatocytes of mice challenged with 
an obesogenic diet result from modulation of only a single pathway. Consistent with this 
concept, our data indicate that several important transcriptional regulators of the hepatic lipid 
and glucose metabolism, predicted or experimentally validated targets of miR-21/miR-21*, are 
significantly affected by deletion of miR-21/miR-21* in mice fed a HFD. Similar deregulation 
of complex transcriptional networks by miR-21 was also previously reported by global gene 
expression profile in liver cancer cells.[24] Restoring the expression and activity of all these 
miR-21/miR-21*-dependent key factors deregulated in the liver of LImiR21KO mice fed a 
HFD (i.e. FOXO1,[49] FOXA2,[50] SREBP1C,[50] STAT3,[51] INSIG2 and HNF4-α)[52] 
to similar levels than those in CTRL mice fed a HFD is technically very challenging. 
Alternatively, complete inhibition of a candidate target of miR-21/miR-21*, through genetic 
deletion or pharmacological inhibition, can lead to cellular effects greatly exceeding the fine 
regulation of these factors by microRNAs. Such experimental approaches may therefore lead 
to over-interpretation of the respective role of a single potential target, or combination of 
them, deregulated by activated miR-21/miR-21*.  Based on our data, a hypothetical model of 
complex interactive networks involving potential miR-21/miR-21* targets and their role in 
regulating the hepatic metabolism is proposed in figure 5E. 
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 miR-21–dependent PPAR- downregulation in hepatic biliary and inflammatory cells was 
reported by Loyer et al as to induce inflammation and fibrosis in a mouse model of 
atherosclerosis (LDLRKO mice) or in mice fed a MCD diet.[53] We could not detect 
significant alterations of PPAR- expression in LImiR21KO mice fed a HFD and expressions 
of enzymes promoting fatty acids oxidation, a process usually stimulated by PPAR- activity, 
were decreased.[54] Therefore our data do not favour a role for miR-21-dependent PPAR- 
downregulation in hepatocytes that could affect fatty acids oxidation and trigger steatosis. 
These differences between our study and the one by Loyer et al., in which different mouse 
models and approaches to inhibit miR-21 are used, underline the complexity of miR-21/miR-
21* target network, the cell-specific and context-dependent effects of miR-21/miR-21*, as 
well as the importance of the experimental approaches used to understand the biological 
functions of miR-21/miR-21*. 
Most of metabolic improvements observed in LImiR21KO mice were actually consistent with 
the drastic downregulation at the mRNA and protein level of PPAR-γ. The decreased 
expression of PPAR-γ, which is not predicted as a miR-21/miR-21* target, could results from 
the combined effects of FOXO1 and HNF4-α, which both can inhibit PPAR-γ but through 
distinct mechanisms (figure 5D).[55, 56] On the other hand, lipogenesis can also be impaired 
in LImiR21KO mice fed a HFD through the upregulation of INSIG2, a predicted target of 
miR-21/miR-21* and a negative regulator of SREBP1C.[57] Considering the capability of 
miR-21 to affect the expression of several target genes, the discrimination between direct and 
indirect effects modulating the downstream genes is complex, in particular in vivo. However, 
from our analyses, it is likely that the beneficial impact of hepatic miR-21 genetic deletion on 
diet-induced metabolic disorders, is not associated with modulation of a single miR-21, or 
miR-21*, target only, but instead is the consequence of fine and concerted alterations in the 
expression of multiple hepatocyte–specific genes. 
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While preparing this manuscript, we also became aware of a study by Wu et al.,[44] who 
described a mechanism involving a HBP1-P53-SREBP1C pathway in the control of diet-
induced steatosis development by miR-21. To this end, they used synthetic inhibitors of miR-
21 in vivo in mice and in vitro in HepG2 cultured cells.[44] In contrast to Wu et al., we did 
not detect up-regulation of HBP1 and only a weak increase (≈30%) of p53 mRNA expression 
in mice genetically deleted for miR-21/miR-21* specifically in hepatocytes and fed a HFD, 
indicating that alternative mechanisms take place in our model. Discrepant results obtained 
with genetic models of miR-21/miR-21* deletion or administration of synthetic miR-21 
inhibitors have already been reported in studies investigating heart pathology for 
example.[33] As well, transformed hepatoma cells (e.g. HepG2 cells) express different 
protein profile, multiple mutations and highly active miR-21 as compared to primary 
hepatocytes, which may lead to different conclusions regarding pathophysiological 
mechanisms occurring in vivo.[58] All together, these considerations suggest cautiousness in 
interpretation of data obtained with the pharmacological inhibitors of single-stranded 
microRNAs.[33] In our study, we bypass these potential issues by generating constitutive 
global miR-21 knockout mice (miR21KO) and liver-specific miR-21 KO mice (LImiR21KO) 
to analyze metabolic defects induced by high fat feeding. LImiR21KO mice are the first mice 
genetically engineered to knockout specifically miR-21/miR-21* in hepatocytes. Furthermore, 
the total lack of the gene results not only in undetectable levels of mature miR-21, but also in 
the loss of the passenger strand, miR-21*, which might influence the observed phenotype.[27, 
28, 29] 
Regarding the enhanced hepatic insulin sensitivity in miR-21/miR-21*-deficient mice, it could 
results from a decreased hepatic steatosis as previously suggested.[59] Additionally, the direct 
modulation of predicted target genes like STAT3 or RICTOR, or indirect targets like IRS2, 
induced by the loss of miR-21/miR-21* might also lead to an improved insulin signalling.[60, 
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61, 62] In particular, and contrary to that previously described in keratinocytes and 
adipocytes,[63, 64] loss of miR-21/miR-21* resulted in an increased hepatic phosphorylation 
of AKT that did not display evident correlation to PTEN levels. It is also of interest that the 
specific down-regulation of G6PC in miR-21/miR-21*-deficient mice fed a HFD could be 
mediated indirectly by STAT3-dependent mechanisms.[65] Since STAT3 is a predicted miR-
21 target gene, it may also regulate some of the metabolic processes altered by the HFD. Of 
note, miR-21-dependent modulation of STAT3 could also represent a potential mechanisms 
contributing to the inflammatory response pushing simple steatosis towards steatohepatitis 
and fibrosis.  
Remarkably, deletion of miR-21/miR-21* in hepatocytes (LImiR21KO mice) alters the ratio 
of lean and fat mass body composition and improves systemic glucose tolerance in mice fed 
with HFD. Although we did not investigated in details the mechanisms behind this phenotype, 
one attractive hypothesis is that deletion of miR-21/miR-21* in hepatocytes triggers a 
crosstalk between the liver and other peripheral organs such as the adipose tissue, muscle or 
pancreas. Such crosstalk between liver and pancreas, mediated by liver-derived soluble 
factors, has been recently reported in mice having a liver-specific deletion of the insulin 
receptor [66] or a liver-specific deletion of PTEN.[37] In this regard, it is interesting to note 
that circulating levels of miR-21 are increased in human patients with NAFLD [43] which 
may potentially impact the adipose tissue physiology. Indeed, recent studies reported a role 
for miR-21 in adipocyte differentiation [67, 68]. Whether circulating miR-21 may promote 
insulin resistance and glucose intolerance in muscle or adipose tissue, thereby explaining the 
increased glucose tolerance observed in LImi21RKO mice fed a HFD, is currently unknown 
and under investigation.  
Finally, future investigations should also shed light on the potential role of miR-21/miR-21* in 
the progression of NAFLD toward more severe stages of liver disease and carcinogenesis and 
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further delineate the potential of miR-21/miR-21* as therapeutic targets for obesity-associated 
insulin resistance, NAFLD, NASH and cancer.  
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FIGURE LEGENDS 
 
Figure 1. Adiposity and energy expenditure in CTRL and miR21KO mice fed a CD or HFD. 
(A) Body weight (n=9-10). (B) Fat and lean body mass by echo-MRI (n=4 for CD, n=9-10 for 
HFD). (C) Food and water intake, (D) O2 consumption and CO2 production and (E) energy 
expenditure with the respective contributions of fat and carbohydrate/protein oxidation (n=4).  
 
Figure 2. Glucose/pyruvate tolerance and steatosis in CTRL and miR21KO mice. Glucose 
(A) and pyruvate (B) tolerance tests in CTRL and miR21KO mice fed a CD or HFD (n=5 for 
CD, n= 4-5 for HFD). (C) Liver/body weight ratio and liver weight (n=10) in mice fed a HFD. 
(D) Representative H&E stained liver histological sections of mice fed a HFD. (E) Hepatic 
triglyceride (TG) and free/esterified cholesterol contents in mice fed a HFD (n=9). 
 
Figure 3. Glucose metabolism and hepatic insulin sensitivity in CTRL and LImiR21KO mice 
fed a HFD. (A) Glucose and pyruvate tolerance tests (n=5). qRT-PCR (n=5) and Western blot 
analysis (n=3) of the expression of hepatic genes/proteins involved in hepatic glycolysis (B) 
and gluconeogenesis (C). (D) Representative Western blots (n=3) and quantifications (n=5) of 
insulin signaling effectors in hepatic tissues. (E) Representative Western blots and 
quantifications (n=4-5) of insulin-induced AKT phosphorylation in mouse primary 
hepatocytes isolated from CTRL and LImiR21KO mice fed a HFD.  
 
Figure 4. Adiposity and hepatic lipid metabolism in CTRL and LImiR21KO mice fed a HFD. 
(A) Body weight, liver weight, and fat/lean body mass (Echo-MRI) (n=5). (B) Representative 
H&E and Oil-red-O (ORO)-stained liver histological sections and quantifications of the lipid 
droplets (LDs) volumes extrapolated from the areas of ORO-stained LDs. Hepatic 
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triglycerides (TG) and cholesterol esters/free cholesterol (n=5). qRT-PCR analysis of the 
expression of hepatic genes involved in lipogenesis (C) and fatty acid uptake (D). (E) 
Representative Western blots analyses (n=3) and quantifications (n=5) of key effectors of the 
hepatic lipid metabolism.  
 
Figure 5. Modulation of predicted and validated miR-21/miR-21* targets regulating the 
hepatic lipid and glucose metabolism in CTRL and LImiR21KO mice fed a HFD. (A) 
Number of prediction softwares (out of 12 using miRwalk 2.0 Atlas) identifying metabolic 
genes targeted by miR-21 (miR-21-5p), or miR-21* (miR-21-3p). (B) Experimentally validated 
targets of miR-21 (miR-21-5p) investigated in this study. qRT-PCR analysis (n=5), 
representative Western blot (n=3) and quantifications (n=5) of transcriptional metabolic 
regulators, which are (C) potentially targeted directly by miR-21/miR-21*, or (D) under the 
control of potential miR-21/miR-21* targets. (E) Hypothetical model of miR-21/miR-21*-
dependent regulatory factors improving the hepatic lipid/glucose metabolism in LImiR21KO 
mice challenged with a HFD. 





